Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)-Reference-Cited by-同舟云学术

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

Published:2018-03-22 Issue:9 Volume:32 Page:1507-1514
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Bissonnette R.¹,Luger T.²,Thaçi D.³,Toth D.⁴,Lacombe A.⁵,Xia S.⁶,Mazur R.⁵,Patekar M.⁵,Charef P.⁵,Milutinovic M.⁵,Leonardi C.⁷,Mrowietz U.⁸^ORCID

Affiliation:

1. Innovaderm Research; Montreal QC Canada

2. Department of Dermatology; University of Münster; Münster Germany

3. Comprehensive Center for Inflammation Medicine; University Hospital Schleswig-Holstein; Lübeck Germany

4. Department of Geriatric and Environmental Dermatology; Probity Medical Research Windsor and XLR8 Medical Research; Windsor ON Canada

5. Novartis Pharma AG; Basel Switzerland

6. Beijing Novartis Pharma Co. Ltd.; Shanghai China

7. Department of Dermatology; Saint Louis University Health Science Center; St Louis MO USA

8. Department of Dermatology; Psoriasis-Center; University Medical Center Schleswig-Holstein; Kiel Germany

Funder

Novartis Pharma

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14878/fullpdf

Reference23 articles.

1. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis;Mease;N Engl J Med,2015

2. Secukinumab in plaque psoriasis-results of two phase 3 trials;Langley;N Engl J Med,2014

3. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study;Blauvelt;J Am Acad Dermatol,2017

4. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial;Thaci;J Am Acad Dermatol,2015

5. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis;Hueber;Sci Transl Med,2010

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients With Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp;Dermatology Practical & Conceptual;2024-04-30

2. Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting;Advances in Rheumatology;2024-04-29

3. Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score;Clinical and Experimental Dermatology;2024-04-15

4. The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials;Clinical, Cosmetic and Investigational Dermatology;2024-04

5. Psoriasis and Related Disorders;Rook's Textbook of Dermatology;2024-03-19